Jun 17, 2020
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
Apr 06, 2020
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Apr 01, 2020
FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
Feb 26, 2020
Hemophilia A - Forecasts for Seven Major Markets Covering the United States, EU5 and Japan
Jan 02, 2020
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Dec 23, 2019
BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
Dec 23, 2019
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Dec 05, 2019
Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home
Jul 19, 2019
Bayer statement on voluntary recall of two lots of Kogenate® FS antihemophilic factor (recombinant) in the United States
Jul 08, 2019
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
Jul 03, 2019
Easing the Burden for People with Hemophilia
Jul 01, 2019
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Jun 26, 2019
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019
Jun 26, 2019
Bayer to present new data from its hemophilia A portfolio at the International Society of Thrombosis and Haemostasis (ISTH) 2019 annual congress
Jun 21, 2019
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
Jun 18, 2019
Health Canada Approves Hemlibra® for Hemophilia A Patients Without Factor VIII Inhibitors
May 28, 2019
BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Dec 04, 2018
Bayer Presents Five-Year Outcomes Data from the PROTECT VIII Extension Study at the 60th American Society of Hematology Annual Meeting
Nov 12, 2018
BioMarin and Believe Limited Announce the Debut of 'Hemophilia: The Musical'
Aug 30, 2018
Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen